Company Page
BrainChild Bio
Founders
BrainChild Bio is a clinical-stage biotechnology company spun out of Seattle Children's Hospital, developing CAR T-cell therapies to treat tumors in the central nervous system. Its lead program, BCB-276, targets DIPG, a rare and fatal pediatric brainstem cancer, and has received FDA Breakthrough Therapy Designation. The company holds an exclusive license to novel CAR T-cell technology developed by Dr. Michael Jensen and his team at Seattle Children's Therapeutics.
Company Founded in 2023
